FDA Approves MARGENZA™
On December 16, 2020, the FDA approved margetuximab-cmkb (MARGENZA™) in combination with chemotherapy, for treating metastatic HER2-positive breast cancer.
SEARCH OUR SITE
for past articles or specific information.
New to Clinical Trials?
Get started on the path to finding a trial for you!
Get started on the path to finding a trial for you!
Select Page